Institutional shares held 20.7 Million
68K calls
52.2K puts
Total value of holdings $216M
$709K calls
$544K puts
Market Cap $291M
28,969,000 Shares Out.
Institutional ownership 71.38%
# of Institutions 81


Latest Institutional Activity in IGMS

Top Purchases

Q3 2024
Siren, L.L.C. Shares Held: 3.33M ($33.4M)
Q3 2024
Invesco Ltd. Shares Held: 223K ($2.24M)
Q3 2024
Northern Trust Corp Shares Held: 192K ($1.92M)
Q3 2024
Wellington Management Group LLP Shares Held: 98.3K ($987K)
Q3 2024
Geode Capital Management, LLC Shares Held: 396K ($3.97M)

Top Sells

Q3 2024
Millennium Management LLC Shares Held: 132K ($1.33M)
Q3 2024
Goldman Sachs Group Inc Shares Held: 1.26M ($12.6M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 4.01M ($40.3M)
Q3 2024
Renaissance Technologies LLC Shares Held: 66.5K ($668K)
Q3 2024
D. E. Shaw & Co., Inc. Shares Held: 97.7K ($981K)

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.


Insider Transactions at IGMS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.59M Shares
From 19 Insiders
Grant, award, or other acquisition 1.06M shares
Conversion of derivative security 113K shares
Open market or private purchase 395K shares
Exercise of conversion of derivative security 18.2K shares
Sell / Disposition
83.5K Shares
From 9 Insiders
Other acquisition or disposition 12.5K shares
Open market or private sale 71K shares

Track Institutional and Insider Activities on IGMS

Follow IGM Biosciences, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IGMS shares.

Notify only if

Insider Trading

Get notified when an Igm Biosciences, Inc. insider buys or sells IGMS shares.

Notify only if

News

Receive news related to IGM Biosciences, Inc.

Track Activities on IGMS